CRBN and myelodysplastic syndrome: Fang et al. [37] showed that Lenalidomide, the main clinically used thalidomide-derived compound, acts through CRBN and has cytotoxic effects in cells of both myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).